 Mark Hoffman
Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 11 | 2022 | 64 | 3.340 |
Why?
| | Decision Support Systems, Clinical | 5 | 2021 | 17 | 1.620 |
Why?
| | Humans | 34 | 2024 | 6896 | 1.120 |
Why?
| | Medical Informatics | 3 | 2022 | 7 | 1.090 |
Why?
| | Genetic Testing | 5 | 2017 | 87 | 1.000 |
Why?
| | Medicine | 1 | 2023 | 10 | 0.880 |
Why?
| | Precision Medicine | 5 | 2016 | 45 | 0.850 |
Why?
| | Databases, Factual | 5 | 2021 | 108 | 0.790 |
Why?
| | Anemia, Sickle Cell | 1 | 2021 | 17 | 0.780 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 20 | 0.770 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 10 | 0.770 |
Why?
| | Information Storage and Retrieval | 2 | 2014 | 5 | 0.760 |
Why?
| | Leukemia | 1 | 2021 | 15 | 0.760 |
Why?
| | Spinal Dysraphism | 1 | 2021 | 9 | 0.750 |
Why?
| | Quality Improvement | 1 | 2021 | 60 | 0.740 |
Why?
| | Genomics | 5 | 2023 | 101 | 0.710 |
Why?
| | Workflow | 2 | 2021 | 6 | 0.680 |
Why?
| | Research Design | 4 | 2023 | 63 | 0.630 |
Why?
| | Child | 12 | 2024 | 3364 | 0.620 |
Why?
| | Consent Forms | 1 | 2017 | 1 | 0.600 |
Why?
| | Genetic Counseling | 1 | 2017 | 9 | 0.590 |
Why?
| | Systems Integration | 2 | 2014 | 6 | 0.560 |
Why?
| | Health Services Research | 1 | 2015 | 4 | 0.520 |
Why?
| | Inpatients | 1 | 2015 | 44 | 0.500 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 45 | 0.480 |
Why?
| | Computational Biology | 3 | 2016 | 43 | 0.440 |
Why?
| | Asthma | 3 | 2024 | 157 | 0.380 |
Why?
| | United States | 5 | 2021 | 669 | 0.360 |
Why?
| | Escherichia coli O157 | 2 | 2006 | 3 | 0.320 |
Why?
| | Antibodies, Bacterial | 2 | 2006 | 8 | 0.320 |
Why?
| | Community-Based Participatory Research | 1 | 2018 | 6 | 0.320 |
Why?
| | Female | 11 | 2024 | 3525 | 0.320 |
Why?
| | Escherichia coli Infections | 2 | 2006 | 19 | 0.320 |
Why?
| | Autistic Disorder | 1 | 2018 | 14 | 0.310 |
Why?
| | Medical Records Systems, Computerized | 2 | 2009 | 4 | 0.290 |
Why?
| | Shiga Toxin 2 | 1 | 2006 | 1 | 0.280 |
Why?
| | Cattle Diseases | 1 | 2006 | 3 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 1 | 2006 | 16 | 0.280 |
Why?
| | Male | 9 | 2024 | 3337 | 0.280 |
Why?
| | Retrospective Studies | 5 | 2022 | 1296 | 0.270 |
Why?
| | Databases, Genetic | 1 | 2006 | 30 | 0.270 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 3 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 231 | 0.240 |
Why?
| | Patient Selection | 1 | 2024 | 40 | 0.230 |
Why?
| | Cohort Studies | 2 | 2024 | 289 | 0.230 |
Why?
| | Bioterrorism | 1 | 2003 | 1 | 0.230 |
Why?
| | Population Surveillance | 1 | 2003 | 13 | 0.230 |
Why?
| | Peripheral Arterial Disease | 1 | 2022 | 2 | 0.210 |
Why?
| | Endovascular Procedures | 1 | 2022 | 5 | 0.210 |
Why?
| | Racism | 1 | 2022 | 8 | 0.200 |
Why?
| | Fructosamine | 1 | 2021 | 1 | 0.200 |
Why?
| | Emergency Medical Services | 1 | 2021 | 14 | 0.200 |
Why?
| | Osteomyelitis | 1 | 2021 | 8 | 0.200 |
Why?
| | Migraine Disorders | 1 | 2021 | 15 | 0.200 |
Why?
| | Commerce | 1 | 2021 | 3 | 0.190 |
Why?
| | Standard of Care | 1 | 2021 | 5 | 0.190 |
Why?
| | Linear Models | 1 | 2021 | 56 | 0.190 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2021 | 8 | 0.190 |
Why?
| | Sleep Apnea Syndromes | 1 | 2021 | 9 | 0.190 |
Why?
| | Appointments and Schedules | 1 | 2021 | 12 | 0.190 |
Why?
| | Fontan Procedure | 1 | 2021 | 19 | 0.190 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 22 | 0.190 |
Why?
| | Liver Diseases | 1 | 2021 | 18 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 36 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2021 | 36 | 0.180 |
Why?
| | Informed Consent | 2 | 2017 | 4 | 0.180 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 23 | 0.180 |
Why?
| | Heart Defects, Congenital | 1 | 2021 | 81 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 37 | 0.170 |
Why?
| | Middle Aged | 3 | 2021 | 608 | 0.170 |
Why?
| | Software | 2 | 2016 | 30 | 0.170 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 39 | 0.170 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 243 | 0.160 |
Why?
| | Research Report | 1 | 2017 | 1 | 0.150 |
Why?
| | Magnesium | 1 | 2017 | 2 | 0.150 |
Why?
| | Myocardial Infarction | 1 | 2017 | 5 | 0.150 |
Why?
| | Genetic Diseases, Inborn | 1 | 2017 | 20 | 0.150 |
Why?
| | Software Design | 1 | 2016 | 1 | 0.140 |
Why?
| | Focus Groups | 1 | 2016 | 12 | 0.140 |
Why?
| | Enterotoxins | 1 | 1996 | 2 | 0.140 |
Why?
| | Staphylococcus aureus | 1 | 1996 | 18 | 0.130 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 115 | 0.130 |
Why?
| | Biomedical Research | 1 | 2016 | 27 | 0.130 |
Why?
| | Adolescent | 4 | 2024 | 2197 | 0.130 |
Why?
| | Florida | 1 | 2014 | 1 | 0.120 |
Why?
| | Molecular Medicine | 1 | 2014 | 1 | 0.120 |
Why?
| | Medical Oncology | 1 | 2014 | 18 | 0.120 |
Why?
| | Young Adult | 3 | 2021 | 647 | 0.120 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 65 | 0.120 |
Why?
| | Lymphocyte Activation | 2 | 2006 | 7 | 0.100 |
Why?
| | User-Computer Interface | 2 | 2016 | 11 | 0.100 |
Why?
| | Infant | 3 | 2021 | 1446 | 0.100 |
Why?
| | Child, Preschool | 3 | 2021 | 1569 | 0.100 |
Why?
| | Family Health | 1 | 2011 | 14 | 0.100 |
Why?
| | Logistic Models | 1 | 2011 | 84 | 0.090 |
Why?
| | Animals | 3 | 2006 | 729 | 0.090 |
Why?
| | Sleep | 2 | 2021 | 37 | 0.090 |
Why?
| | Data Collection | 2 | 2021 | 29 | 0.090 |
Why?
| | Delivery of Health Care | 3 | 2016 | 33 | 0.090 |
Why?
| | Risk Factors | 2 | 2022 | 487 | 0.090 |
Why?
| | Adult | 3 | 2021 | 1181 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2022 | 622 | 0.080 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 45 | 0.080 |
Why?
| | Cattle | 2 | 2006 | 24 | 0.080 |
Why?
| | Patient Outcome Assessment | 1 | 2018 | 8 | 0.080 |
Why?
| | Research Personnel | 1 | 2018 | 4 | 0.080 |
Why?
| | Advisory Committees | 1 | 2018 | 9 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2018 | 24 | 0.080 |
Why?
| | Family | 1 | 2018 | 27 | 0.080 |
Why?
| | Congresses as Topic | 2 | 2020 | 9 | 0.080 |
Why?
| | Aged | 2 | 2021 | 378 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2021 | 816 | 0.070 |
Why?
| | Drug Resistance, Viral | 1 | 2007 | 2 | 0.070 |
Why?
| | Pharmacogenetics | 1 | 2009 | 176 | 0.070 |
Why?
| | HIV | 1 | 2007 | 4 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2007 | 9 | 0.070 |
Why?
| | Database Management Systems | 1 | 2006 | 2 | 0.070 |
Why?
| | HIV Infections | 1 | 2007 | 50 | 0.070 |
Why?
| | Cytogenetics | 1 | 2005 | 2 | 0.060 |
Why?
| | Human Genome Project | 1 | 2005 | 3 | 0.060 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 3 | 0.060 |
Why?
| | Geographic Information Systems | 1 | 2024 | 14 | 0.060 |
Why?
| | Disease Notification | 1 | 2003 | 1 | 0.060 |
Why?
| | Electronics, Medical | 1 | 2003 | 3 | 0.060 |
Why?
| | Mutation | 1 | 2005 | 212 | 0.060 |
Why?
| | Laboratories | 1 | 2003 | 14 | 0.060 |
Why?
| | Kansas | 1 | 2003 | 43 | 0.060 |
Why?
| | Limb Salvage | 1 | 2022 | 4 | 0.050 |
Why?
| | Ischemia | 1 | 2022 | 7 | 0.050 |
Why?
| | Critical Illness | 1 | 2022 | 22 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2022 | 19 | 0.050 |
Why?
| | Genome, Human | 1 | 2022 | 86 | 0.050 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 42 | 0.050 |
Why?
| | Acute Disease | 1 | 2021 | 79 | 0.050 |
Why?
| | Time Factors | 1 | 2022 | 250 | 0.050 |
Why?
| | Data Mining | 1 | 2021 | 5 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 85 | 0.050 |
Why?
| | Health Care Costs | 1 | 2021 | 33 | 0.050 |
Why?
| | Outpatients | 1 | 2021 | 27 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 37 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2021 | 151 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 35 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 137 | 0.040 |
Why?
| | Length of Stay | 1 | 2021 | 233 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 130 | 0.040 |
Why?
| | Age Factors | 1 | 2021 | 210 | 0.040 |
Why?
| | Computer Communication Networks | 1 | 2020 | 2 | 0.040 |
Why?
| | Canada | 1 | 2020 | 31 | 0.040 |
Why?
| | Europe | 1 | 2020 | 37 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2021 | 47 | 0.040 |
Why?
| | Obesity | 1 | 2021 | 125 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 336 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 24 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 1998 | 9 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2017 | 22 | 0.040 |
Why?
| | Survival Rate | 1 | 2017 | 83 | 0.040 |
Why?
| | Biomarkers | 1 | 2017 | 136 | 0.040 |
Why?
| | Prognosis | 1 | 2017 | 211 | 0.030 |
Why?
| | Confidentiality | 1 | 2016 | 5 | 0.030 |
Why?
| | Information Dissemination | 1 | 2016 | 8 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 1996 | 7 | 0.030 |
Why?
| | Histidine | 1 | 1996 | 2 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1996 | 19 | 0.030 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1996 | 11 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 1996 | 29 | 0.030 |
Why?
| | Vomiting | 1 | 1996 | 23 | 0.030 |
Why?
| | National Human Genome Research Institute (U.S.) | 1 | 2016 | 1 | 0.030 |
Why?
| | Macaca mulatta | 1 | 1996 | 24 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 1996 | 31 | 0.030 |
Why?
| | Mice | 1 | 1996 | 348 | 0.030 |
Why?
| | Neoplasms | 1 | 2014 | 128 | 0.030 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2009 | 25 | 0.020 |
Why?
| | Pilot Projects | 1 | 2009 | 120 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 214 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 348 | 0.020 |
Why?
| | HIV Protease | 1 | 2007 | 1 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
| | Nelfinavir | 1 | 2007 | 1 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 2007 | 1 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2007 | 2 | 0.020 |
Why?
| | HIV Protease Inhibitors | 1 | 2007 | 2 | 0.020 |
Why?
| | Viral Load | 1 | 2007 | 14 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2007 | 33 | 0.020 |
Why?
| | Algorithms | 1 | 2007 | 105 | 0.020 |
Why?
| | Genotype | 1 | 2007 | 410 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 150 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|